ORG-24598 is a selective inhibitor of the type 1 glycine transporter.[1]

Potential uses

Alcohol use disorder

A test in rats has showed that combining varenicline, bupropion, and an indirect glycine agonist (such as ORG-24598) could be beneficial for treatment of alcohol use disorder.[2]

Schizophrenia

Studies have shown that glycine re-uptake inhibitors selective for the type 1 transporter may be useful for the treatment of certain schizophrenia symptoms.[3][4]

References

  1. ^ "2-[methyl-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]acetic acid". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-17.
  2. ^ Olsson, Yasmin; Lidö, Helga; Ademar, Karin; Cadeddu, Davide; Ericson, Mia; Söderpalm, Bo (January 2024). "The GlyT1-inhibitor Org 24598 facilitates the alcohol deprivation abolishing and dopamine elevating effects of bupropion + varenicline in rats". Journal of Neural Transmission (Vienna, Austria: 1996). 131 (1): 95–106. doi:10.1007/s00702-023-02701-x. ISSN 1435-1463. PMC 10769923. PMID 37773223.
  3. ^ Chue, Pierre (2013). "Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)". Current Pharmaceutical Design. 19 (7): 1311–1320. doi:10.2174/138161213804805766. ISSN 1873-4286. PMID 23194655.
  4. ^ Javitt, Daniel C. (July 2002). "Glycine modulators in schizophrenia". Current Opinion in Investigational Drugs. 3 (7): 1067–1072. ISSN 1472-4472. PMID 12186269.
Allikas: https://en.wikipedia.org/wiki/ORG-24598
No tags for this post.